A regulatory trial shows that a weekly tablet taken once a week is just as reliable as the traditional therapy in which patients must take a pill daily. The study tested the combination of the drugs Islatravir and Lenacapavir in adults whose HIV infection was already well controlled. By random assignment, they received either the new weekly tablet or their current daily triple therapy of Bictegravir, Emtricitabine, and Tenofovir Alafenamide. “There was no development of resistance,” Rockstroh told the German Press Agency. He pointed out that when antiviral combination therapy was introduced in 1996, HIV medications had to be taken three times a day.